B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.

Mult Scler Relat Disord · 2020 · PMC7219389 · PMID 32460086

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

did not reach statistical significancep-value=0.059so close (0.05 < p ≤ 0.1)

The difference in the proportion of patients on different DMT categories between the two groups did not reach statistical significance (Fisher's exact test p-value=0.059): 62% of patients in the COVID-19-suspect group were on a B-cell depleting antibody while only 41% patient in the rest of participants (the none-COVID-19-suspect group) were on B-cell depleting medications.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.